Johnson & Johnson Reports 2020 Third-Quarter Results

   THIRD QUARTER   

  ($ in Millions, except EPS)  

   2020   

   2019   

   %  Change   

   Reported Sales   

  $ 21,082  

  $ 20,729  

  1.7%  

   Net Earnings   

  3,554  

  1,753  

  102.7%  

   EPS (diluted)   

  $      1.33  

  $      0.66  

  101.5%  

   Non-GAAP*   

   THIRD QUARTER   

  ($ in Millions, except EPS)  

   2020   

   2019   

   %  Change   

   Operational Sales   ^1,2    

  N/A  

  N/A  

  1.7%  

   Adjusted Operational Sales   ^1,3    

  N/A  

  N/A  

  2.0%  

   Adjusted Net Earnings   ^1,4    

  5,868  

  5,672  

  3.5%  

   Adjusted EPS (diluted)   ^1,4    

  $      2.20  

  $      2.12  

  3.8%  

   ¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules  

   ² Excludes the impact of translational currency  

   ³ Excludes the net impact of acquisitions and divestitures and translational currency  

   ⁴ Excludes intangible amortization expense and special items  

   THIRD QUARTER   

   %  Change   

  
($ in Millions) ¹  

    
2020    ²    

    
2019    ²    

    
Reported    ²    

    
Operational    ^1,2    

    
Currency    ²    

   Adjusted
Operational   ^1,3    

   U.S.   

  $ 11,086  

  $ 10,791  

  2.7%  

  2.7%  

  -  

  2.8  

   International   

  9,996  

  9,938  

  0.6%  

  0.6%  

  0.0  

  1.1  

   Worldwide   

  $ 21,082  

  $ 20,729  

  1.7%  

  1.7%  

  0.0  

  2.0  

   ¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules  

   ² Excludes the impact of translational currency  

   ³ Excludes the net impact of acquisitions and divestitures and translational currency  

  Note: values may have been rounded  

   THIRD QUARTER   

   %  Change   

  
($ in Millions) ¹  

    
2020    ¹    

    
2019    ¹    

    
Reported    ²    

    
Operational    ^1,2    

    
Currency    ¹    

   Adjusted
Operational   ^1,3    

   Consumer Health   

  $       3,514  

  $       3,469  

  1.3%  

  3.0  

  (1.7)  

  3.1  

   Pharmaceutical   

  11,418  

  10,877  

  5.0%  

  4.6  

  0.4  

  4.7  

   Medical Devices   

  6,150  

  6,383  

  (3.6)%  

  (3.9)  

  0.3  

  (3.3)  

   Worldwide   

  $     21,082  

  $     20,729  

  1.7%  

  1.7  

  0.0  

  2.0  

   ¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules  

   ² Excludes the impact of translational currency  

   ³ Excludes the net impact of acquisitions and divestitures and translational currency  

  Note: values may have been rounded  

  Regulatory Approvals  

  THERMOCOOL SMARTTOUCH – Biosense Webster Receives FDA Approval for SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation¹  

   (press release)   

  SIMPONI ARIA (golimumab) – Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older  

   (press release)   

  SPRAVATO (esketamine) – Janssen Announces U.S. FDA Approval of CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior  

   (press release)   

  DARZALEX (daratumumab) – U.S. FDA Approves New DARZALEX-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma  

   (press release)   

  STELARA (ustekinumab) – U.S. Food and Drug Administration Approves Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis  

   (press release)   

  Regulatory Submissions  

  UPTRAVI (selexipag) – Janssen Submits New Drug Application (NDA) to U.S. FDA for Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)  

   (press release)   

  DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – Janssen Submits Application Seeking U.S. FDA Approval for the Treatment of Patients with Light Chain (AL) Amyloidosis  

   (press release)   

  Other  

  Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate ¹  

   (press release)   

  Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.¹  

   (press release)   

  Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate  

   (press release)   

  CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment  

   (press release)   

  Johnson & Johnson Announces that Janssen's COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies  

   (press release)   

  Janssen to Discontinue Pimodivir Influenza Development Program  

   (press release)   

  Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine  

   (press release)   

  U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology  

   (press release)   

   ¹ Subsequent to the quarter  

    October 2020    

    July 2020    

  ($ in Billions, except EPS)  

  Adjusted Operational Sales ^1,2  

  Change vs. Prior Year  

  0.5% – 1.5%  

  (0.8%) – 1.0%  

  Operational Sales ²  

  Change vs. Prior Year  

  $82.0 to $82.8  

  0.0% – 1.0%  

  $81.0 to $82.5  

  (1.3%) – 0.5%  

  Estimated Reported Sales ³  

  Change vs. Prior Year  

  $81.2 to $82.0  

  (1.0%) – 0.0%  

  $79.9 to $81.4  

  (2.6%) – (0.8%)  

  Adjusted Operational EPS (Diluted) ^2,4  

  Change vs. Prior Year  

  $7.95 to $8.05  

  (8.4%) - (7.3%)  

  $7.85 to $8.05  

  (9.6%) - (7.3%)  

  Adjusted EPS (Diluted) ^3,4  

  Change vs. Prior Year  

  $7.95 to $8.05  

  (8.4%) – (7.3%)  

  $7.75 to $7.95  

  (10.7%) – (8.4%)  

   ¹ Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures  

   ² Non-GAAP financial measure; excludes the impact of translational currency  

   ³ Calculated using Euro Average Rate: October 2020 = $1.14 Euro Average Rate: July 2020 = $1.12 (Illustrative purposes only)  

   ⁴ Non-GAAP financial measure; excludes intangible amortization expense and special items  

   Johnson & Johnson and Subsidiaries   

   Supplementary Sales Data   

  (Unaudited; Dollars in Millions)  

   THIRD QUARTER   

   NINE MONTHS   

  Percent Change  

  Percent Change  

   2020   

   2019   

  Total  

  Operations  

  Currency  

   2020   

   2019   

  Total  

  Operations  

  Currency  

   Sales to customers by   

   segment of business   

  Consumer Health  

  U.S.  

   $   1,556   

   1,394   

  11.6  

  %  

  11.6  

  -  

   $   4,853   

   4,369   

  11.1  

  %  

  11.1  

  -  

  International  

   1,958   

   2,075   

  (5.6)  

  (2.7)  

  (2.9)  

   5,582   

   5,962   

  (6.4)  

  (2.2)  

  (4.2)  

   3,514   

   3,469   

  1.3  

  3.0  

  (1.7)  

   10,435   

   10,331   

  1.0  

  3.4  

  (2.4)  

  Pharmaceutical  

  U.S.  

   6,438   

   6,340   

  1.5  

  1.5  

  -  

   18,619   

   17,705   

  5.2  

  5.2  

  -  

  International  

   4,980   

   4,537   

  9.7  

  8.8  

  0.9  

   14,685   

   13,945   

  5.3  

  7.4  

  (2.1)  

   11,418   

   10,877   

  5.0  

  4.6  

  0.4  

   33,304   

   31,650   

  5.2  

  6.1  

  (0.9)  

  Medical Devices  

  U.S.  

   3,092   

   3,057   

  1.2  

  1.2  

  -  

   7,852   

   9,249   

  (15.1)  

  (15.1)  

  -  

  International  

   3,058   

   3,326   

  (8.1)  

  (8.5)  

  0.4  

   8,518   

   10,082   

  (15.5)  

  (14.1)  

  (1.4)  

   6,150   

   6,383   

  (3.6)  

  (3.9)  

  0.3  

   16,370   

   19,331   

  (15.3)  

  (14.6)  

  (0.7)  

  U.S.  

   11,086   

   10,791   

  2.7  

  2.7  

  -  

   31,324   

   31,323   

  0.0  

  0.0  

  -  

  International  

   9,996   

   9,938   

  0.6  

  0.6  

  0.0  

   28,785   

   29,989   

  (4.0)  

  (1.7)  

  (2.3)  

  Worldwide  

   $ 21,082   

   20,729   

  1.7  

  1.7  

  0.0  

   $ 60,109   

   61,312   

  (2.0)  

  (0.8)  

  (1.2)  

   Note : Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.  

   Johnson & Johnson and Subsidiaries   

   Supplementary Sales Data   

  (Unaudited; Dollars in Millions)  

   THIRD QUARTER   

   NINE MONTHS   

  Percent Change  

  Percent Change  

   2020   

   2019   

  Total  

  Operations  

  Currency  

   2020   

   2019   

  Total  

  Operations  

  Currency  

   Sales to customers by   

   geographic area   

  U.S.  

   $ 11,086   

   10,791   

  2.7  

  %  

  2.7  

  -  

   $ 31,324   

   31,323   

  0.0  

  %  

  0.0  

  -  

  Europe  

   4,819   

   4,461   

  8.0  

  4.6  

  3.4  

   13,709   

   13,803   

  (0.7)  

  0.1  

  (0.8)  

  Western Hemisphere excluding U.S.  

   1,296   

   1,488   

  (12.9)  

  (1.2)  

  (11.7)  

   3,931   

   4,446   

  (11.6)  

  (0.4)  

  (11.2)  

  Asia-Pacific, Africa  

   3,881   

   3,989   

  (2.7)  

  (3.2)  

  0.5  

   11,145   

   11,740   

  (5.1)  

  (4.3)  

  (0.8)  

  International  

   9,996   

   9,938   

  0.6  

  0.6  

  0.0  

   28,785   

   29,989   

  (4.0)  

  (1.7)  

  (2.3)  

  Worldwide  

   $ 21,082   

   20,729   

  1.7  

  %  

  1.7  

  0.0  

   $ 60,109   

   61,312   

  (2.0)  

  %  

  (0.8)  

  (1.2)  

   Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.  

   Johnson & Johnson and Subsidiaries   

   Condensed Consolidated Statement of Earnings   

   (Unaudited; in Millions Except Per Share Figures)   

   THIRD QUARTER   

   2020   

   2019   

  Percent  

   Percent   

   Percent   

  Increase  

   Amount   

   to Sales   

   Amount   

   to Sales   

  (Decrease)  

   Sales to customers   

   $ 21,082   

   100.0   

   $ 20,729   

   100.0   

  1.7  

   Cost of products sold   

   6,972   

   33.1   

   6,867   

   33.1   

  1.5  

   Gross Profit   

   14,110   

   66.9   

   13,862   

   66.9   

  1.8  

   Selling, marketing and administrative expenses   

   5,431   

   25.8   

   5,374   

   26.0   

  1.1  

   Research and development expense   

   2,840   

   13.5   

   2,599   

   12.5   

  9.3  

   In-process research and development   

   138   

   0.6   

   -   

   -   

   Interest (income) expense, net   

   32   

   0.1   

   (41)   

   (0.2)   

   Other (income) expense, net   

   1,200   

   5.7   

   4,214   

   20.3   

   Restructuring   

   68   

   0.3   

   69   

   0.4   

   Earnings before provision for taxes on income   

   4,401   

   20.9   

   1,647   

   7.9   

  167.2  

   Provision for/(Benefit from) taxes on income   

   847   

   4.0   

   (106)   

   (0.6)   

   Net earnings   

   $   3,554   

   16.9   

   $   1,753   

   8.5   

  102.7  

   Net earnings per share (Diluted)   

   $     1.33   

   $     0.66   

  101.5  

   Average shares outstanding (Diluted)   

   2,669.3   

   2,669.9   

   Effective tax rate   

   19.2   

   %   

   (6.4)   

   %   

   Adjusted earnings before provision for taxes and net earnings   ⁽¹⁾    

   Earnings before provision for taxes on income   

   $   7,246   

   34.4   

   $   7,116   

   34.3   

  1.8  

   Net earnings   

   $   5,868   

   27.8   

   $   5,672   

   27.4   

  3.5  

   Net earnings per share (Diluted)   

   $     2.20   

   $     2.12   

  3.8  

   Effective tax rate   

   19.0   

   %   

   20.3   

   %   

   ⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.  

   Johnson & Johnson and Subsidiaries   

   Condensed Consolidated Statement of Earnings   

   (Unaudited; in Millions Except Per Share Figures)   

   NINE MONTHS   

   2020   

   2019   

  Percent  

   Percent   

   Percent   

  Increase  

   Amount   

   to Sales   

   Amount   

   to Sales   

  (Decrease)  

   Sales to customers   

   $    60,109   

   100.0   

   $    61,312   

   100.0   

  (2.0)  

   Cost of products sold   

   20,613   

   34.3   

   20,422   

   33.3   

  0.9  

   Gross Profit   

   39,496   

   65.7   

   40,890   

   66.7   

  (3.4)  

   Selling, marketing and administrative expenses   

   15,627   

   26.0   

   16,139   

   26.3   

  (3.2)  

   Research and development expense   

   8,127   

   13.5   

   8,123   

   13.3   

  0.0  

   In-process research and development   

   144   

   0.3   

   890   

   1.4   

   Interest (income) expense, net   

   16   

   0.0   

   (43)   

   (0.1)   

   Other (income) expense, net   

   545   

   0.9   

   2,509   

   4.1   

   Restructuring   

   187   

   0.3   

   162   

   0.3   

   Earnings before provision for taxes on income   

   14,850   

   24.7   

   13,110   

   21.4   

  13.3  

   Provision for taxes on income   

   1,874   

   3.1   

   2,001   

   3.3   

  (6.3)  

   Net earnings   

   $    12,976   

   21.6   

   $    11,109   

   18.1   

  16.8  

   Net earnings per share (Diluted)   

   $        4.86   

   $        4.13   

  17.7  

   Average shares outstanding (Diluted)   

   2,670.8   

   2,688.1   

   Effective tax rate   

   12.6   

   %   

   15.3   

   %   

   Adjusted earnings before provision for taxes and net earnings   ⁽¹⁾    

   Earnings before provision for taxes on income   

   $    19,827   

   33.0   

   $    22,597   

   36.9   

  (12.3)  

   Net earnings   

   $    16,468   

   27.4   

   $    18,283   

   29.8   

  (9.9)  

   Net earnings per share (Diluted)   

   $        6.17   

   $        6.80   

  (9.3)  

   Effective tax rate   

   16.9   

   %   

   19.1   

   %   

   ⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.  

   Johnson & Johnson and Subsidiaries   

   Reconciliation of Non-GAAP Financial Measures   

   Third Quarter   

   Nine Months Ended   

  (Dollars in Millions Except Per Share Data)  

   2020   

   2019   

   2020   

   2019   

  Net Earnings, after tax- as reported  

   $3,554   

   $1,753   

   $12,976   

   $11,109   

   Pre-tax Adjustments   

  Intangible Asset Amortization expense  

  1,181  

  1,138  

  3,426  

  3,386  

  Litigation expense, net  

  1,477  

  4,000  

  2,210  

  4,832  

  IPR&D  

  138  

  -  

  144  

  890  

  Restructuring related  

  130  

  128  

  363  

  360  

  Acquisition and Integration related ¹  

  (154)  

  107  

  (1,087)  

  229  

  Unrealized (gains)/losses on securities  

  32  

  89  

  (174)  

  (217)  

  Medical Device Regulation ²  

  38  

  -  

  89  

  -  

  Other  

  3  

  7  

  6  

  7  

   Tax Adjustments   

  Tax impact on special item adjustments ³  

  (482)  

  (1,159)  

  (1,002)  

  (1,922)  

  Tax legislation and related impacts  

  (49)  

  (391)  

  (483)  

  (391)  

  Adjusted Net Earnings, after tax  

   $5,868   

   $5,672   

   $16,468   

   $18,283   

  Average shares outstanding (Diluted)  

  2,669.3  

  2,669.9  

  2,670.8  

  2,688.1  

  Adjusted net earnings per share (Diluted)  

   $2.20   

   $2.12   

   $6.17   

   $6.80   

  Operational adjusted net earnings per share (Diluted)  

   $2.17   

   $6.18   

   Notes:   

   ¹  

  Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition.  

   ²  

  European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations.  The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.  

   ³  

  The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.  

   Johnson & Johnson and Subsidiaries   

   Reconciliation of Non-GAAP Financial Measure   

    Adjusted Operational Sales Growth    

   THIRD QUARTER 2020 ACTUAL vs. 2019 ACTUAL   

   Segments   

   Consumer Health   

   Pharmaceutical   

   Medical Devices   

   Total   

   WW As Reported   

   1.3%   

   5.0%   

   (3.6)%   

   1.7%   

  U.S.  

  11.6%  

  1.5%  

  1.2%  

  2.7%  

  International  

  (5.6)%  

  9.7%  

  (8.1)%  

  0.6%  

   WW Currency   

   (1.7)   

   0.4   

   0.3   

   0.0   

  U.S.  

   -   

   -   

   -   

   -   

  International  

  (2.9)  

  0.9  

  0.4  

  0.0  

   WW Operational   

   3.0%   

   4.6%   

   (3.9)%   

   1.7%   

  U.S.  

  11.6%  

  1.5%  

  1.2%  

  2.7%  

  International  

  (2.7)%  

  8.8%  

  (8.5)%  

  0.6%  

   General Surgery   

    Advanced Sterilization Products    

   0.5   

   0.2   

  U.S.  

  0.0  

  0.0  

  International  

  0.9  

  0.4  

   Baby Care   

    Baby Center    

   0.1   

   0.0   

  U.S.  

  0.4  

  0.1  

  International  

  0.0  

  0.0  

   All Other Acquisitions and Divestitures   

   0.0   

   0.1   

   0.0   

   0.1   

  U.S.  

  0.0  

  0.0  

  0.1  

  0.0  

  International  

  (0.1)  

  0.3  

  0.0  

  0.1  

   WW Adjusted Operational   

   3.1%   

   4.7%   

   (3.3)%   

   2.0%   

  U.S.  

  12.0%  

  1.5%  

  1.3%  

  2.8%  

  International  

  (2.8)%  

  9.2%  

  (7.6)%  

  1.1%  

   Note: Percentages are based on actual, non-rounded figures and may not sum  

   Johnson & Johnson and Subsidiaries   

   Reconciliation of Non-GAAP Financial Measure   

    Adjusted Operational Sales Growth    

   NINE MONTHS 2020 ACTUAL vs. 2019 ACTUAL   

   Segments   

   Consumer Health   

   Pharmaceutical   

   Medical Devices   

   Total   

   WW As Reported   

   1.0%   

   5.2%   

   (15.3)%   

   (2.0)%   

  U.S.  

  11.1%  

  5.2%  

  (15.1)%  

  0.0%  

  International  

  (6.4)%  

  5.3%  

  (15.5)%  

  (4.0)%  

   WW Currency   

   (2.4)   

   (0.9)   

   (0.7)   

   (1.2)   

  U.S.  

   -   

   -   

   -   

   -   

  International  

  (4.2)  

  (2.1)  

  (1.4)  

  (2.3)  

   WW Operational   

   3.4%   

   6.1%   

   (14.6)%   

   (0.8)%   

  U.S.  

  11.1%  

  5.2%  

  (15.1)%  

  0.0%  

  International  

  (2.2)%  

  7.4%  

  (14.1)%  

  (1.7)%  

   Skin Health / Beauty   

    Dr. Ci Labo - Japan    

   (0.1)   

   0.0   

  U.S.  

  0.0  

  0.0  

  International  

  (0.2)  

  0.0  

   General Surgery   

    Advanced Sterilization Products    

   0.9   

   0.3   

  U.S.  

  0.8  

  0.3  

  International  

  0.9  

  0.4  

   Baby Care   

    Baby Center    

   0.2   

   0.0   

  U.S.  

  0.6  

  0.1  

  International  

  0.0  

  0.0  

   All Other Acquisitions and Divestitures   

   (0.1)   

   0.2   

   0.0   

   0.1   

  U.S.  

  0.0  

  0.0  

  0.0  

  0.0  

  International  

  (0.1)  

  0.3  

  0.0  

  0.1  

   WW Adjusted Operational   

   3.4%   

   6.3%   

   (13.7)%   

   (0.4)%   

  U.S.  

  11.7%  

  5.2%  

  (14.3)%  

  0.4%  

  International  

  (2.6)%  

  7.7%  

  (13.1)%  

  (1.3)%  

   Note: Percentages are based on actual, non-rounded figures and may not sum  

    REPORTED SALES vs. PRIOR PERIOD ($MM)    

    REPORTED SALES vs. PRIOR PERIOD ($MM)    

   THIRD QUARTER   

   NINE MONTHS   

   % Change   

   % Change   

    2020    

    2019    

    Reported    

    Operational    ⁽¹⁾      

    Currency    

    2020    

    2019    

    Reported    

    Operational    ⁽¹⁾      

    Currency    

    CONSUMER HEALTH SEGMENT    ^(2,3)      

   OTC   

  US  

   $         601   

   477   

  26.0%  

  26.0%  

  -  

   $        1,917   

   1,468   

  30.6%  

  30.6%  

  -  

  Intl  

   541   

   621   

  -12.9%  

  -12.9%  

  0.0%  

   1,722   

   1,781   

  -3.3%  

  -0.6%  

  -2.7%  

  WW  

   1,142   

   1,098   

  4.0%  

  4.0%  

  0.0%  

   3,639   

   3,249   

  12.0%  

  13.5%  

  -1.5%  

   SKIN HEALTH / BEAUTY   ⁽⁴⁾    

  US  

   572   

   559   

  2.4%  

  2.4%  

  -  

   1,767   

   1,810   

  -2.4%  

  -2.4%  

  -  

  Intl  

   577   

   592   

  -2.7%  

  -0.5%  

  -2.2%  

   1,506   

   1,633   

  -7.8%  

  -4.9%  

  -2.9%  

  WW  

   1,149   

   1,151   

  -0.2%  

  0.9%  

  -1.1%  

   3,273   

   3,443   

  -5.0%  

  -3.6%  

  -1.4%  

   ORAL CARE   

  US  

   164   

   156   

  5.5%  

  5.5%  

  -  

   510   

   462   

  10.4%  

  10.4%  

  -  

  Intl  

   248   

   223   

  10.7%  

  14.4%  

  -3.7%  

   694   

   673   

  3.0%  

  7.9%  

  -4.9%  

  WW  

   412   

   379   

  8.5%  

  10.8%  

  -2.3%  

   1,204   

   1,135   

  6.0%  

  8.9%  

  -2.9%  

   BABY CARE   

  US  

   91   

   91   

  -1.0%  

  -1.0%  

  -  

   279   

   277